Full Press Release Details
EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe.
REGN
EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe
Key Takeaway: EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe